KAMADA LTD
corporate_fare Company Profile
KAMADA LTD (NASDAQ:KMDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for KMDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for KMDA spans 4, 6-K, 20-F.
Recent high-impact activity:
- Director David Tsur Sells $1.46M of Kamada Shares
- Kamada CFO Chaime Orlev to Depart After 9 Years; Q2 Revenue Rises 23%
- Kamada Q2 Revenue Beats by 8%, Reaffirms 2026 Outlook
- Record H1 Revenue and EBITDA Drive Kamada's 2026 Guidance Affirmation; CFO Departure Announced
- Kamada's $50M Plasma Deal Validates Its U.S. Collection Hub Strategy
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for KMDA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-09.
New $50M Shelf Registration Filed · No Immediate Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
KMDA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.